Angela Castoli

Dr. Angela Castoli

Keizo Asami Immunopathology Laboratory, Federal University of Pernambuco, Pernambuco, Brazil
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Immunity
Verified
Journal Article
Open access
ARAnneleen Remmerie
Anneleen Remmerie
LMLiesbet Martens
Liesbet Martens
TTTinne Thoné
Tinne Thoné
ACAngela Castoli
Angela Castoli
RSRuth Seurinck
Ruth Seurinck
CSCharlotte L. Scott
Charlotte L. Scott
Metabolic-associated fatty liver disease (MAFLD) represents a spectrum of disease states ranging from simple steatosis to non-alcoholic steatohepatitis (NASH). Hepatic macrophages, specifically Kupffer cells (KCs), are suggested to play important roles in the pathogenesis of MAFLD through their activation, although the exact roles played by these cells remain unclear. Here, we demonstrated that KCs were reduced in MAFLD being replaced by macrophages originating from the bone marrow. Recruited macrophages existed in two subsets with distinct activation states, either closely resembling homeostatic KCs or lipid-associated macrophages (LAMs) from obese adipose tissue. Hepatic LAMs expressed Osteopontin, a biomarker for patients with NASH, linked with the development of fibrosis. Fitting with this, LAMs were found in regions of the liver with reduced numbers of KCs, characterized by increased Desmin expression. Together, our data highlight considerable heterogeneity within the macrophage pool and suggest a need for more specific macrophage targeting strategies in MAFLD.

1 November 2021 in Cell Metabolism
Verified
Journal Article
Closed access
DEDaniel Erny
Daniel Erny
NDNikolaos Dokalis
Nikolaos Dokalis
CMCharlotte Mezö
Charlotte Mezö
ACAngela Castoli
Angela Castoli
OMOmar Mossad
Omar Mossad
MPMarco Prinz
Marco Prinz

1 August 2015 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
VAVinicius Andrade-Oliveira
Vinicius Andrade-Oliveira
MAMariane T. Amano
Mariane T. Amano
MCMatheus Correa-Costa
Matheus Correa-Costa
ACAngela Castoli
Angela Castoli
RFRaphael Jose Ferreira Felizardo
Raphael Jose Ferreira Felizardo
NCNiels Olsen Saraiva Camara
Niels Olsen Saraiva Camara
Short-chain fatty acids (SCFAs) are fermentation end products produced by the intestinal microbiota and have anti-inflammatory and histone deacetylase–inhibiting properties. Recently, a dual relationship between the intestine and kidneys has been unraveled. Therefore, we evaluated the role of SCFA in an AKI model in which the inflammatory process has a detrimental role. We observed that therapy with the three main SCFAs (acetate, propionate, and butyrate) improved renal dysfunction caused by injury. This protection was associated with low levels of local and systemic inflammation, oxidative cellular stress, cell infiltration/activation, and apoptosis. However, it was also associated with an increase in autophagy. Moreover, SCFAs inhibited histone deacetylase activity and modulated the expression levels of enzymes involved in chromatin modification. In vitro analyses showed that SCFAs modulated the inflammatory process, decreasing the maturation of dendritic cells and inhibiting the capacity of these cells to induce CD4+ and CD8+ T cell proliferation. Furthermore, SCFAs ameliorated the effects of hypoxia in kidney epithelial cells by improving mitochondrial biogenesis. Notably, mice treated with acetate-producing bacteria also had better outcomes after AKI. Thus, we demonstrate that SCFAs improve organ function and viability after an injury through modulation of the inflammatory process, most likely via epigenetic modification.

5 January 2016 in Frontiers in Immunology
Verified
Journal Article
Open access
ACAngela Castoli
Angela Castoli
CSCristiane Naffah de Souza
Cristiane Naffah de Souza
NCNiels Olsen Saraiva Camara
Niels Olsen Saraiva Camara
Pedro M Moraes-VieiraPedro M Moraes-Vieira
Pedro M Moraes-Vieira
Immune cell infiltration in (white) adipose tissue during obesity is associated with the development of insulin resistance. In adipose tissue, the main population of leukocytes are macrophages. Macrophages can be classified into two major populations: M1, classically activated macrophages, and M2, alternatively activated macrophages, although recent studies have identified a broad range of macrophage subsets. During obesity, adipose tissue M1 macrophage numbers increase and correlate with adipose tissue inflammation and insulin resistance. Upon activation, pro-inflammatory M1 macrophages induce aerobic glycolysis. By contrast, in lean humans and mice, the number of M2 macrophages predominates. M2 macrophages secrete anti-inflammatory cytokines and utilize oxidative metabolism to maintain adipose tissue homeostasis. Here we review the immunologic and metabolic functions of adipose tissue macrophages and their different facets in obesity and the metabolic syndrome.

13 January 2017 in Scientific Reports
Verified
Journal Article
Open access
TBTarcio Teodoro Braga
Tarcio Teodoro Braga
MFMaria Fernanda Forni
Maria Fernanda Forni
MCMatheus Correa-Costa
Matheus Correa-Costa
RRRodrigo Nalio Ramos
Rodrigo Nalio Ramos
JBJosé Alexandre Marzagao Barbuto
José Alexandre Marzagao Barbuto
NCNiels Olsen Saraiva Camara
Niels Olsen Saraiva Camara
Uric acid is a damage-associated molecular pattern (DAMP), released from ischemic tissues and dying cells which, when crystalized, is able to activate the NLRP3 inflammasome. Soluble uric acid (sUA) is found in high concentrations in the serum of great apes, and even higher in some diseases, before the appearance of crystals. In the present study, we sought to investigate whether uric acid, in the soluble form, could also activate the NLRP3 inflammasome and induce the production of IL-1β. We monitored ROS, mitochondrial area and respiratory parameters from macrophages following sUA stimulus. We observed that sUA is released in a hypoxic environment and is able to induce IL-1β release. This process is followed by production of mitochondrial ROS, ASC speck formation and caspase-1 activation.Nlrp3−/−macrophages presented a protected redox state, increased maximum and reserve oxygen consumption ratio (OCR) and higher VDAC protein levels when compared to WT andMyd88−/−cells. Using a disease model characterized by increased sUA levels, we observed a correlation between sUA, inflammasome activation and fibrosis. These findings suggest sUA activates the NLRP3 inflammasome. We propose that future therapeutic strategies for renal fibrosis should include strategies that block sUA or inhibit its recognition by phagocytes.

1 August 2019 in Cell Metabolism
Verified
Journal Article
Open access
DPDaniel J. Puleston
Daniel J. Puleston
MBMichael D. Buck
Michael D. Buck
RGRamon Klein Geltink
Ramon Klein Geltink
RKRyan L. Kyle
Ryan L. Kyle
GCGeorge Caputa
George Caputa
EPErika L. Pearce
Erika L. Pearce
How cells adapt metabolism to meet demands is an active area of interest across biology. Among a broad range of functions, the polyamine spermidine is needed to hypusinate the translation factor eukaryotic initiation factor 5A (eIF5A). We show here that hypusinated eIF5A (eIF5AH) promotes the efficient expression of a subset of mitochondrial proteins involved in the TCA cycle and oxidative phosphorylation (OXPHOS). Several of these proteins have mitochondrial targeting sequences (MTSs) that in part confer an increased dependency on eIF5AH. In macrophages, metabolic switching between OXPHOS and glycolysis supports divergent functional fates stimulated by activation signals. In these cells, hypusination of eIF5A appears to be dynamically regulated after activation. Using in vivo and in vitro models, we show that acute inhibition of this pathway blunts OXPHOS-dependent alternative activation, while leaving aerobic glycolysis-dependent classical activation intact. These results might have implications for therapeutically controlling macrophage activation by targeting the polyamine-eIF5A-hypusine axis.